{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(1)"],"submitter":["Keam SP"],"funding":["Peter MacCallum Foundation","Cancer Council Victoria","Victorian Cancer Agency","National Health and Medical Research Council","Prostate Cancer Foundation"],"pubmed_abstract":["<h4>Background</h4>Prostate cancer (PCa) has a profoundly immunosuppressive microenvironment and is commonly immune excluded with few infiltrative lymphocytes and low levels of immune activation. High-dose radiation has been demonstrated to stimulate the immune system in various human solid tumors. We hypothesized that localized radiation therapy, in the form of high dose-rate brachytherapy (HDRBT), would overcome immune suppression in PCa.<h4>Methods</h4>To investigate whether HDRBT altered prostate immune context, we analyzed preradiation versus postradiation human tissue from a cohort of 24 patients with localized PCa that received HDRBT as primary treatment (RadBank cohort). We performed Nanostring immune gene expression profiling, digital spatial profiling, and high-throughput immune "],"journal":["Journal for immunotherapy of cancer"],"pagination":["e000792"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7319782"],"repository":["biostudies-literature"],"pubmed_title":["High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot."],"pmcid":["PMC7319782"],"pubmed_authors":["Sandhu S","Keam SP","Halse H","Caramia F","Nguyen T","Neeson PJ","Van Kooten Losio N","Darcy PK","Wang M","Byrne DJ","Ryland G","Blombery P","Haupt Y","Mitchell C","Williams SG","Haupt S"],"additional_accession":[]},"is_claimable":false,"name":"High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot.","description":"<h4>Background</h4>Prostate cancer (PCa) has a profoundly immunosuppressive microenvironment and is commonly immune excluded with few infiltrative lymphocytes and low levels of immune activation. High-dose radiation has been demonstrated to stimulate the immune system in various human solid tumors. We hypothesized that localized radiation therapy, in the form of high dose-rate brachytherapy (HDRBT), would overcome immune suppression in PCa.<h4>Methods</h4>To investigate whether HDRBT altered prostate immune context, we analyzed preradiation versus postradiation human tissue from a cohort of 24 patients with localized PCa that received HDRBT as primary treatment (RadBank cohort). We performed Nanostring immune gene expression profiling, digital spatial profiling, and high-throughput immune ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jun","modification":"2026-07-15T22:13:48.961Z","creation":"2026-07-09T10:19:51.03Z"},"accession":"S-EPMC7319782","cross_references":{"pubmed":["32581061"],"doi":["10.1136/jitc-2020-000792"]}}